Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Times Interest Earned (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Times Interest Earned for 10 consecutive years, with $4.78 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Times Interest Earned rose 168.05% year-over-year to $4.78, compared with a TTM value of -$7.89 through Dec 2025, up 33.33%, and an annual FY2025 reading of -$7.89, up 33.33% over the prior year.
  • Times Interest Earned was $4.78 for Q4 2025 at Zevra Therapeutics, up from $2.02 in the prior quarter.
  • Across five years, Times Interest Earned topped out at $364.56 in Q2 2021 and bottomed at -$604.07 in Q2 2022.
  • Average Times Interest Earned over 5 years is -$79.16, with a median of -$27.87 recorded in 2024.
  • Peak annual rise in Times Interest Earned hit 16729.21% in 2021, while the deepest fall reached 35406.82% in 2021.
  • Year by year, Times Interest Earned stood at -$568.4 in 2021, then skyrocketed by 90.42% to -$54.43 in 2022, then soared by 64.35% to -$19.41 in 2023, then skyrocketed by 63.79% to -$7.03 in 2024, then soared by 168.05% to $4.78 in 2025.
  • Business Quant data shows Times Interest Earned for ZVRA at $4.78 in Q4 2025, $2.02 in Q3 2025, and -$35.36 in Q2 2025.